Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Pedro R. Lowenstein"'
Autor:
Brandon L. McClellan, Mahmoud S. Alghamri, Rohit Thalla, Pedro R. Lowenstein, Maria G. Castro
Publikováno v:
STAR protocols. 3(2)
Here, we present a mass cytometry protocol optimized to examine the phenotype of immune cells within the mouse glioma microenvironment, using a Sleeping Beauty transposon-mediated mouse glioma model. We describe antibody conjugation and titrations fo
Autor:
Karen Eddy, Maria B. Garcia-Fabiani, Ruthvik Avvari, Ayman Taher, Brandon L. McClellan, Dolores Hambardzumyan, Maria Ventosa, Joshua D. Welch, Sofia D. Merajver, Syed M Faisal, Wajd N. Al-Holou, Maria G. Castro, Santiago Haase, Jason Heth, Chao Gao, Parag G. Patil, Felipe J Nunez, Rohit Thalla, Mahmoud S. Alghamri, Margaret S. Hartlage, Li Zhang, Gabriel Núñez, Shawn L. Hervey-Jumper, Pedro R. Lowenstein, Neha Kamran, Peter J. Ulintz, Jialin Liu, Daniel A. Orringer, Stephen Carney
Publikováno v:
Science Advances
Description
Mutant IDH1 gliomas are infiltrated by nonsuppressive immature myeloid cells, resulting in enhanced response to immunotherapy.
Mutant isocitrate-dehydrogenase 1 (mIDH1) synthesizes the oncometabolite 2-hydroxyglutarate (2HG), wh
Mutant IDH1 gliomas are infiltrated by nonsuppressive immature myeloid cells, resulting in enhanced response to immunotherapy.
Mutant isocitrate-dehydrogenase 1 (mIDH1) synthesizes the oncometabolite 2-hydroxyglutarate (2HG), wh
Autor:
Gabriel Núñez, Robert Doherty, Padma Kadiyala, Maria G. Castro, Diana Shah, Syed M Faisal, Daniel Zamler, Andrea Comba, Pedro R. Lowenstein, Gregory J. Baker, Mahmoud S. Alghamri
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
Although pharmacological stimulation of TLRs has anti-tumor effects, it has not been determined whether endogenous stimulation of TLRs can lead to tumor rejection. Herein, we demonstrate the existence of an innate anti-glioma NK-mediated circuit init
Autor:
Fernando M. Nunez, Felipe J Nunez, Pedro R. Lowenstein, Anna Schwendeman, Padma Kadiyala, Maria G. Castro, Dan Li, Maria B. Garcia-Fabiani
Publikováno v:
Neuro Oncol
Patients with mutant IDH1 gliomas survive ~3.8 year longer than patients harboring wildtype IDH1 glioma, irrespective of histology or genetic lesions, making mutant IDH1 an essential prognostic indicator. Mutant IDH1 gliomas are highly infiltrative w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78c3df3c67481ac2133287d9bf3608da
https://europepmc.org/articles/PMC6847445/
https://europepmc.org/articles/PMC6847445/
Autor:
Maria G. Castro, Pedro R. Lowenstein
Publikováno v:
Clinical Immunology. 189:43-51
Glioma cells are one of the most aggressive and malignant tumors. Following initial surgery, and radio-chemotherapy they progress rapidly, so that patients' median survival remains under two years. They invade throughout the brain, which makes them d
Publikováno v:
Clinical Immunology. 189:34-42
Various preclinical studies have demonstrated that the success of immunotherapeutic strategies in inhibiting tumor progression in animal models of Glioblastoma multiforme (GBM). It is also evident that tumor-induced immune suppression drastically imp
Autor:
Meghna Saxena, Pedro R. Lowenstein, Youping Li, Maria G. Castro, Neha Kamran, Nicholas Raja, Padma Kadiyala, Diana Shah, Mariela A. Moreno-Ayala, Marianela Candolfi
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Survival of glioma (GBM) patients treated with the current standard of care remains dismal. Immunotherapeutic approaches that harness the cytotoxic and memory potential of the host immune system have shown great benefit in other cancers. GBMs have de
Autor:
Maria G. Castro, Pedro R. Lowenstein, Yohei Mineharu, Gregory J. Baker, Anda Alexandra Calinescu, Neha Kamran
Publikováno v:
Immunotherapy. 7:1073-1104
In the last decade, numerous studies of immunotherapy for malignant glioma (glioblastoma multiforme) have brought new knowledge and new hope for improving the prognosis of this incurable disease. Some clinical trials have reached Phase III, following
Autor:
Pedro R. Lowenstein, Maria G. Castro
Publikováno v:
Clinical Cancer Research. 22:4760-4762
A novel approach to immunization against glioma tumors is described. Immunization against 11 antigens expressed in malignant brain tumors elicits responses to one or more antigens in a large percentage of patients. This novel approach suggests that i
Molecular characterization studies have led to uncover the genetic signatures and methylation status of gliomas and correlate these with clinical prognosis. These studies have illustrated that mutation in isocitrate dehydrogenase (mIDH1), and far les
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6cf5eac15e2d932acf19146b36aa10
https://europepmc.org/articles/PMC5692029/
https://europepmc.org/articles/PMC5692029/